Filed by Automated Filing Services Inc. (604) 609-0244 - Titan Trading Corp. - Exhibit 4.3






 Exhibit 4.3

 Dr. Ken Powell 

  Mr. Thomas Kreilein 

  200 – 675 West Hastings Street 

  Vancouver, British Columbia 

  V6B 1N2  


June 3, 2003


 Phillip S. Carrozza II 

  375 Ocean Road 

  Narragansett, Rhode Island 

  02882 


Dear Phil:


 Re:        Titan Trading Analytics
  Inc. (the “Company”) – Grant of License  

 In further consideration of your agreement to license your
  securities trading technology to the Company (the “Licensing Agreement”),
  and in consideration of your payment of $1.00 to us, the receipt and sufficiency
  of which we hereby acknowledge, we agree as follows: 

	1.	We will transfer 1,550,000
        and option to you a total of 500,000 common shares in the Company’s
        capital to you over a 24-month period as follows:

	 	 	 
	 	a) 
	upon execution of this agreement and the Licensing
        Agreement, we will grant you a call option whereby you may purchase from
        us 250,000 common shares at $0.10 each for a period of two years from
        that date;

	 	 	 
	 	b) 
	on August 31, 2003, we will grant you a call option
        whereby you may purchase from us an additional 250,000 common shares at
        $0.10 each for a period of two years from that date;

	 	 	 
	 	c) 
	on November 30, 2003, we will transfer an additional
        250,000 common shares to you;

	 	 	 
	 	d) 
	on May 31, 2004, we will transfer an additional 250,000
        common shares to you; and

	 	 	 
	 	e)
	on May 31, 2005, transfer an additional 1,050,000
        common shares to you.



 If the Company terminates the Licensing Agreement in accordance
  with paragraph 3.10 therein, the above call options shall immediately terminate
  and we will not have the obligation to make any subsequent share transfers to
  you.




 

	2.	Should the closing price
        of the Company’s common shares as traded on the TSX Venture Exchange
        fail to meet each of the following minimum benchmarks by the dates indicated,
        you shall have the option of terminating the Licensing Agreement by providing
        us with notice in writing:

	 	 	 
	 	a) 
	CDN$0.25 by July 31, 2003;

	 	 b) 
	CDN$0.50 by November 30, 2003; 

	 	c) 
	CDN$1.00 by May 30, 2004.

	 	 	 
	 	(each of the above is a
        “Cause for Termination”)

	 	 	 
	3.	If you fail to provide us
        with written notice that you are terminating the Licensing Agreement within
        10 days of the occurrence of a Cause for Termination, you may not terminate
        the Licensing Agreement until another Cause for Termination occurs.

	 	 	 
	4.	Upon receipt of the termination
        notice described in paragraph 2, we will forthwith cause the Company to
        terminate the Licensing Agreement and return all rights relating to your
        securities trading technology to you, whereupon you shall have no further
        obligation to us from that time forward. However, we shall be entitled
        to receipt of any Profit Interest (as defined in the Licensing Agreement)
        due to us up to the date of the termination notice.

	 	 	 
	5.	Should our shares close
        at a price of CDN$5.00 or higher for 60 consecutive trading days, you
        shall be entitled to a bonus of CDN$200,000.00 either, at our option,
        in the form of free trading common shares of the Company or cash. If we
        decide to pay this bonus in shares, the deemed price shall be the average
        TSX Venture Exchange closing market price of the Company’s common
        shares on the five trading days immediately preceding and the five trading
        days immediately following the date the bonus payment obligation is triggered.



 If the foregoing accurately sets out the terms of the agreement
  reached between us, please indicate by signing below and returning a duly executed
  copy of this letter to us whereupon there will be a binding and legally enforceable
  agreement between us. 

	Yours truly,	 	AGREED AND ACCEPTED this ____ day
	Dr. Ken Powell	 	of June, 2003
	 
	 	 
	 
	 	 
	 
	 	 
	Dr. Ken Powell
	 	Phil Carrozza
	 
	 	 
	 
	 	 
	Thomas Kreilein